Medite Cancer Diagnostics Inc (PK:MDIT)

Business Focus: Advanced Medical Equipment & Technology

Nov 15, 2017 08:00 am ET
MEDITE Cancer Diagnostics Appoints Joel Kanter To Its Board As An Independent Director
ORLANDO, Fla., Nov. 15, 2017 (GLOBE NEWSWIRE) -- MEDITE Cancer Diagnostics, Inc. (OTCQB:MDIT) (the “Company”), specializing in the development, manufacturing and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and...
Nov 14, 2017 05:25 pm ET
MEDITE Cancer Diagnostics Reports 2017 Third Quarter Financial Results
Launch of New Products Supported by Expanded Manufacturing Footprint
Nov 08, 2017 08:31 am ET
MEDITE Cancer Diagnostics Reports Appointments of New Chairman of the Board and Chief Executive Officer
ORLANDO, Fla., Nov. 08, 2017 (GLOBE NEWSWIRE) -- MEDITE Cancer Diagnostics, Inc. (OTCQB:MDIT) (the “Company”), specializing in the development, manufacturing and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and...
Aug 14, 2017 05:00 pm ET
MEDITE Cancer Diagnostics Reports 2017 Second Quarter and First Six Month Financial Results
MEDITE Cancer Diagnostics, Inc. (OTCQB: MDIT) (the "Company"), specializing in the development, manufacturing and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions, today announced its 2017 second quarter and first six month financial results.
Jul 27, 2017 08:00 am ET
MEDITE Cancer Diagnostics to Launch SureCyte(TM) C1 Stain Globally at the 29th European Congress of Pathology
MEDITE Cancer Diagnostics, Inc. (OTCQB: MDIT), specializing in the development, manufacturing and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions, announced today that it will launch its SureCyte™ C1 fluorogenic instant staining product globally at the 29th Annual European Congress of Pathology in Amsterdam, Netherlands from September 2-5, 2017.
May 10, 2017 09:01 am ET
MEDITE Cancer Diagnostics Announces Reorganization of Germany Operations
MEDITE Cancer Diagnostics, Inc. (OTCQB: MDIT) (the "Company") specializing in the development, manufacturing and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions, announces further restructuring of its organization in Germany to position the Company for revenue growth and profitability.
Apr 28, 2017 09:01 am ET
MEDITE Cancer Diagnostics Announces Reorganization of Germany Operations
MEDITE Cancer Diagnostics, Inc. (OTCQB: MDIT) (the "Company") specializing in the development, manufacturing and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions, announced the restructuring of its organization in Germany to position the Company for revenue growth and profitability.
Apr 27, 2017 04:01 pm ET
MEDITE Cancer Diagnostics Appoints Susan Weisman as Chief Financial Officer
MEDITE Cancer Diagnostics, Inc. (OTCQB: MDIT) (the "Company"), specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions, today announced the appointment of Susan Weisman as Chief Financial Officer
Mar 07, 2017 09:29 am ET
MEDITE Cancer Diagnostics Appoints Eric M. Goehausen to Board of Directors
MEDITE Cancer Diagnostics, Inc. (OTCQB: MDIT) ("MEDITE" or the "Company"), a medical technology company specializing in the development, engineering, manufacturing and marketing of premium medical devices and consumables for detection, risk assessment and diagnosis of cancer and related diseases, today announced that Mr. Eric M. Goehausen has been elected to MEDITE's Board of Directors.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.